Kimberly-Clark
KMB
$97.04
-0.31%
Kimberly-Clark Corp. is a global leader in the consumer defensive sector, manufacturing and marketing a wide range of essential personal care and consumer tissue products under iconic brands such as Huggies, Kleenex, and Cottonelle. The company operates as a dominant, established player in the household and personal products industry, leveraging its strong brand portfolio and extensive distribution network. The current investor narrative is heavily focused on the pending acquisition of Kenvue's consumer health portfolio in the second half of 2026, which represents a significant strategic expansion, alongside ongoing debates about the stock's valuation as it trades near multi-year lows amidst a challenging revenue and margin environment.…
KMB
Kimberly-Clark
$97.04
Related headlines
KMB 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Kimberly-Clark's 12-month outlook, with a consensus price target around $126.15 and implied upside of +30.0% versus the current price.
Average Target
$126.15
3 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
3
covering this stock
Price Range
$78 - $126
Analyst target range
Analyst coverage is limited, with only 3 analysts providing estimates, indicating this large-cap stock suffers from relatively low institutional research interest which can contribute to higher volatility and less efficient price discovery. The consensus sentiment appears neutral to cautious, as evidenced by recent institutional ratings including a mix of 'Hold', 'Neutral', 'Equal Weight', and a 'Sell' from Citigroup, with only Piper Sandler maintaining an 'Overweight' rating. Without a provided consensus price target, the implied upside or downside cannot be calculated, but the wide dispersion in analyst views—from 'Sell' to 'Overweight'—signals high uncertainty regarding the company's near-term trajectory, particularly around the integration of the planned Kenvue acquisition and its impact on growth and margins.
Bulls vs Bears: KMB Investment Factors
The evidence currently tilts bearish, as the severe revenue contraction, high leverage, and negative price momentum present immediate and tangible risks that outweigh the attractive valuation and dividend yield. The most important tension in the investment debate is whether the stock's deep value discount (16.63x PE vs. 22x sector average) correctly anticipates a fundamental stabilization and successful Kenvue integration, or if it merely reflects a justified pricing of a company in secular decline facing margin pressure and debt concerns. The resolution of this tension hinges on the next few quarters of revenue and margin performance ahead of the 2026 acquisition.
Bullish
- Deep Value on PE vs. Sector: KMB trades at a trailing PE of 16.63x, a 24% discount to the industry average of 22x. The forward PE of 12.91x suggests the market is pricing in earnings growth, potentially from the Kenvue acquisition or cost savings, making the stock appear undervalued relative to peers.
- Strong Free Cash Flow & Dividend: The company generates robust annual free cash flow of $2.38 billion, supporting a high dividend yield of 4.94% with an 82% payout ratio. This provides significant income support and signals financial resilience despite operational headwinds.
- Valuation at Multi-Year Lows: The stock price of $97.67 is just 32.8% of its 52-week range ($92.42-$144.31) and its trailing PE of 16.63x is near the bottom of its historical range, which has often exceeded 20x. This indicates most negative expectations may already be priced in.
- Defensive Profile with Low Beta: KMB's beta of 0.296 indicates it is approximately 70% less volatile than the broader market. This defensive characteristic should provide downside protection in a market downturn, appealing to risk-averse investors.
Bearish
- Severe Revenue Contraction: Q4 2025 revenue of $4.08B declined -17.21% YoY, following a sequential drop from $4.84B in Q1 2025. This persistent top-line erosion, not an isolated event, raises fundamental questions about the company's growth trajectory and market share.
- High Financial Leverage: A debt-to-equity ratio of 4.77 indicates significant financial leverage, which elevates risk, especially in a rising interest rate environment. This constrains financial flexibility and amplifies earnings volatility.
- Operating Margin Compression: Operating margins have compressed from 15.89% in Q1 2025 to 12.43% in Q4 2025, reflecting ongoing cost inflation or competitive pressures that are eroding profitability despite the company's scale and brand power.
- Pronounced Negative Momentum: The stock is in a sustained downtrend with a 1-year price change of -24.79% and a staggering -53.83 relative strength versus the SPY. A 1-month bounce of 10.25% lacks conviction, as the 3-month change remains negative at -2.32%.
KMB Technical Analysis
The stock is in a pronounced and sustained downtrend, evidenced by a 1-year price change of -24.79% and a 6-month decline of -18.41%. With a current price of $97.67, the stock is trading at just 32.8% of its 52-week range ($92.42 to $144.31), positioning it much closer to its annual low than its high, which suggests a deep value opportunity but also reflects significant negative momentum and fundamental concerns. Recent short-term momentum shows a slight divergence, with a 1-month gain of 10.25% against the starkly negative longer-term trends; however, this positive 1-month move is overshadowed by a -2.32% change over the last 3 months, indicating the recent uptick lacks conviction and may be a temporary bounce within a broader bearish structure. The stock's beta of 0.296 indicates it is approximately 70% less volatile than the broader market (SPY), which is typical for a defensive staple but has not shielded it from severe underperformance, as shown by a staggering -53.83 relative strength versus the SPY over the past year. Key technical levels are clearly defined, with immediate support at the 52-week low of $92.42 and major resistance at the 52-week high of $144.31; a decisive break below support could signal a new leg down, while reclaiming levels above $110 would be necessary to suggest a meaningful trend reversal is underway.
Beta
0.31
0.31x market volatility
Max Drawdown
-35.3%
Largest decline past year
52-Week Range
$92-$144
Price range past year
Annual Return
-27.6%
Cumulative gain past year
| Period | KMB Return | S&P 500 |
|---|---|---|
| 1m | +0.5% | +8.2% |
| 3m | -10.4% | +9.0% |
| 6m | -6.7% | +10.5% |
| 1y | -27.6% | +26.5% |
| ytd | -4.3% | +8.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
KMB Fundamental Analysis
Revenue growth is stagnant to declining, with the most recent quarterly revenue of $4.08 billion representing a -17.21% year-over-year contraction; this follows a sequential decline from $4.84 billion in Q1 2025, indicating persistent top-line pressure rather than an isolated event. The company remains profitable with a net income of $499 million in Q4 2025, but profitability metrics are mixed, as the net margin of 12.23% is supported by a gross margin of 35.91%, though operating margins have compressed from 15.89% in Q1 2025 to 12.43% in Q4 2025, reflecting cost inflation or competitive pressures. The balance sheet carries significant financial leverage with a debt-to-equity ratio of 4.77, which elevates risk, but this is partially offset by robust cash generation, including trailing twelve-month free cash flow of $2.38 billion and a current ratio of 0.75, indicating adequate, though not strong, short-term liquidity to manage obligations.
Quarterly Revenue
$4.1B
2025-12
Revenue YoY Growth
-0.17%
YoY Comparison
Gross Margin
+0.35%
Latest Quarter
Free Cash Flow
$2.4B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is KMB Overvalued?
Given a positive net income, the primary valuation metric is the Price-to-Earnings (PE) ratio. The trailing PE stands at 16.63x, while the forward PE is lower at 12.91x; this discount in the forward multiple implies the market expects earnings to recover or grow, potentially factoring in benefits from the Kenvue acquisition or cost-saving initiatives. Compared to sector averages, KMB's trailing PE of 16.63x trades at a discount to the provided industry average PE of 22x (a 24% discount), which may be justified by its recent revenue declines and high financial leverage, though its stable dividend yield of 4.94% offers a yield support. Historically, the stock's current trailing PE of 16.63x is near the bottom of its own historical range, as seen in ratios from 2023-2025 where PE often exceeded 20x and reached as high as 114x in mid-2023; this suggests the market is currently pricing in pessimistic expectations, creating a potential value scenario if fundamentals stabilize.
PE
16.6x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 13x~114x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
12.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are elevated. The company carries a high debt-to-equity ratio of 4.77, which increases interest expense sensitivity and limits strategic optionality. Concurrently, revenue is contracting sharply (-17.21% YoY in Q4 2025), and operating margins are compressing (down over 300 bps from Q1 to Q4 2025), indicating core business pressures. While strong free cash flow of $2.38B provides a buffer, a weak current ratio of 0.75 points to potential liquidity strain in managing short-term obligations alongside this debt load.
Market & Competitive Risks center on valuation and execution. Although trading at a discount to the sector, KMB's low valuation may persist if revenue declines continue, reflecting a 'value trap'. The stock has shown extreme underperformance versus the market (-53.83 relative strength), suggesting a severe loss of investor confidence that may not reverse quickly. The major upcoming catalyst, the Kenvue acquisition, carries significant integration and execution risk, potentially distracting management and straining the balance sheet further in a competitive consumer staples landscape.
Worst-Case Scenario involves a continuation of the current downtrend exacerbated by a failed acquisition or further margin erosion. In this adverse scenario, the stock could re-test and break its 52-week low of $92.42. Given the stock's historical max drawdown of -35.92%, a realistic downside from the current price of $97.67 could be in the range of -20% to -30%, bringing the price down to the $68-$78 range if sentiment completely sours and the dividend safety comes into question. The most immediate damage would be a break below $92.42 support, potentially triggering a new leg down.